临床酶药物的目标环境
Susan Klaeger1,2,3, Stephanie Heinzlmeir1,2,3, Mathias Wilhelm1
1Chair of Proteomics and Bioanalytics, Technical University of Munich (TUM), Freising, Germany.
概括
这项研究使用化学蛋白质学来绘制243种激酶抑制剂的点,揭示了新的药物点和非点. 这些发现有助于癌症药物发现和临床决策,
科学领域:
- 生物化学
- 药理学
- 癌症学
背景情况:
- 激酶抑制剂是关键的癌症治疗药物,但多药学需要目标解.
- 了解药物点对于阐明作用机制和优化治疗策略至关重要.
研究的目的:
- 通过化学蛋白质学全面分析临床评估的酶药物的目标谱.
- 确定现有激酶抑制剂的新目标,非目标和潜在的治疗应用.
- 整合蛋白学数据以精制药物受影响的途径并识别反应标志物.
主要方法:
- 用化学蛋白质学分析了243种激酶抑制剂的向作用.
- 综合了蛋白分析以评估药物诱导的途径调节.
- 案例研究表明了转化价值,包括SIK2抑制,MELK向和卡博桑提尼布重定位.
主要成果:
- 已确定的激酶抑制剂的前所未有的目标被确定.
- 一个全面的视图
结论:
- 这种蛋白质组资源为酶抑制剂多药学提供了宝贵的见解.
- 这些发现有助于基础研究,临床应用和癌症治疗药物的发现.
- 数据整合有助于识别特定瘤突变的组合治疗和药物重新定位.
相关概念视频
Transducer Mechanism: Enzyme-Linked Receptors
4.2K
Enzyme-linked receptors are cell-surface receptors acting as an enzyme or associating with an enzyme intracellularly. They make excellent drug targets. Drugs can bind to the extracellular ligand-binding domain or directly affect their enzymatic domain and alter their activity.
Major types that are helpful drug targets include:
Major types that are helpful drug targets include:
4.2K
Targeted Cancer Therapies
9.0K
The targeted cancer therapies, also known as “molecular targeted therapies,” take advantage of the molecular and genetic differences between the cancer cells and the normal cells. It needs a thorough understanding of the cancer cells to develop drugs that can target specific molecular aspects that drive the growth, progression, and spread of cancer cells without affecting the growth and survival of other normal cells in the body.
There are several types of targeted therapies against...
There are several types of targeted therapies against...
9.0K
Treatment for Pulmonary Arterial Hypertension: Receptor Tyrosine Kinase Inhibitors and Calcium Channel Blockers
568
Receptor tyrosine kinase inhibitors (TKIs) and calcium channel blockers (CCBs) are two critical categories of drugs employed in the treatment of pulmonary artery hypertension (PAH). PAH is a disease that causes high blood pressure in the pulmonary arteries, resulting in chest pain, fatigue, and shortness of breath.
TKIs, such as imatinib (Gleevec), are particularly effective in tackling the growth and mitogenic factors that become upregulated in PAH patients. These factors contribute to the...
TKIs, such as imatinib (Gleevec), are particularly effective in tackling the growth and mitogenic factors that become upregulated in PAH patients. These factors contribute to the...
568
Targets for Drug Action: Overview
10.6K
Drugs target macromolecules to modify ongoing cellular processes. Primary drug targets include receptors, ion channels, transporters, and enzymes.
Receptors are either membrane-spanning or intracellular proteins, which upon binding a ligand, get activated and transmit the signal downstream to elicit a response. Drugs bind receptors, either mimicking the action of endogenous ligands or blocking the receptor activity to bring about a modified response. Nearly 35% of approved drugs target the G...
Receptors are either membrane-spanning or intracellular proteins, which upon binding a ligand, get activated and transmit the signal downstream to elicit a response. Drugs bind receptors, either mimicking the action of endogenous ligands or blocking the receptor activity to bring about a modified response. Nearly 35% of approved drugs target the G...
10.6K
Clinical Trials: Overview
5.1K
Clinical development focuses on how the drug will interact with the human body and encompasses four key phases of clinical trials, each serving a specific purpose in assessing the safety and effectiveness of new drugs. These phases overlap and build upon one another. Phase I involves a small group of healthy volunteers (typically 20-80 individuals) or, in cases where significant toxicity is expected, patients with the targeted disease, such as cancer or AIDS. The volunteers are tested for...
5.1K
Combination Therapies and Personalized Medicine
6.2K
Combining two or more treatment methods increases the life span of cancer patients while reducing damage to vital organs or tissue from the overuse of a single treatment. Combination therapy also targets different cancer-inducing pathways, thus reducing the chances of developing resistance to treatment.
The combination of the drug acetazolamide and sulforaphane is a good example of combination therapy to treat cancer. The cells in the interior of a large tumor often die due to the hypoxic and...
The combination of the drug acetazolamide and sulforaphane is a good example of combination therapy to treat cancer. The cells in the interior of a large tumor often die due to the hypoxic and...
6.2K


